Alanyl-glutamine in peritoneal dialysis fluids - a randomized controlled phase I/II trial. Homo sapiens

In this open-label randomized controlled phase I/II trial, 20 stable peritoneal dialysis patients underwent two 4 h dwells with acidic glucose-based PDF, with and without 8 mM alanyl-glutamine (AlaGln) in a cross-over design. Unsupervised hierarchical clustering of transcriptomics data suggested specific effects of AlaGln in patients who had previously suffered from peritonitis. Overall design: Expression profiles could be generated from 3 patients' RNA under both treatment conditions in the study.